N'-(6-chloropyridazin-3-yl)benzohydrazide | 7190-96-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N'-(6-chloropyridazin-3-yl)benzohydrazide
• 英文别名: 3-benzoylhydrazino-6-chloropyridazine；benzoic acid N'-(6-chloro-pyridazin-3-yl)-hydrazide；6-Chlor-3-benzoylhydrazinopyridazin
• CAS: 7190-96-7
• 化学式: C₁₁H₉ClN₄O
• 分子量: 248.672
• InChiKey: UMCXKZPSQMSKAU-UHFFFAOYSA-N

物化性质

• 沸点：
  414.2±30.0 °C(Predicted)
• 密度：
  1.416±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N'-(6-chloropyridazin-3-yl)benzohydrazide 生成 1,2,4-噻唑[4,3-b]吡嗪e, 6-氯-3-苯基-
  参考文献：
  名称：

  Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold

  摘要：

  Leucine rich repeat kinase 2 (LRRK2) has been genetically linked to Parkinson's disease (PD). The most common mutant, G2019S, increases kinase activity, thus LRRK2 kinase inhibitors are potentially useful in the treatment of PD. We herein disclose the structure, potential ligand-protein binding interactions, and pharmacological profiling of potent and highly selective kinase inhibitors based on a triazolopyridazine chemical scaffold. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.07.052
• 作为产物：
  描述：

  3-氯-6-肼基哒嗪 、 苯甲酰氯 以 乙腈 为溶剂， 反应 2.0h， 生成 N'-(6-chloropyridazin-3-yl)benzohydrazide
  参考文献：
  名称：

  Structure-based design of 3-aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase

  摘要：

  A series of substituted 3-aryl-6-amino-triazolo[4,3-b]pyridazines were identified as highly selective inhibitors of Pim-1 kinase. Initial exploration identified compound 24 as a potent, selective inhibitor, limited in its utility by poor solubility and permeability. Understanding the unusual ATP-binding site of the Pim kinases and X-ray crystallographic data on compound 24 led to design improvements in this class of inhibitor. This resulted in compound 29, a selective, soluble and permeable inhibitor of Pim-1. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.04.061

文献信息

• Synthesis and Conformational Analysis of [3-(6-Chloropyridazin-3-yl)-3,4-Dihydropyridazino[4,5-b]Quinoxalin-2(1Н)-yl](Phenyl)Methanone
  作者：A. I. Karkhut、K. B. Bolibrukh、S. V. Polovkovych、O. Khoumeri、O. S. Solovyov、T. Terme、P. Vanelle、V. P. Novikov

  DOI：10.1007/s10593-014-1489-0

  日期：2014.6

  [3-(6-Chloropyridazin-3-yl)-3,4-dihydropyridazino[4,5-b]quinoxalin-2(1H)-yl](phenyl)methanone has been synthesized and its two stable forms were isolated. For the establishment of their structures, B3LYP geometry and energy and GIAO/B3LYP NMR calculations of possible conformers using the polarizable continuum model were performed. The differences in calculated spectra allow attributing calculated structures

  合成了[3-（6-氯代哒嗪-3-基）-3,4-二氢哒嗪并[4,5-b]喹喔啉-2（1H）-基]（苯基）甲酮，并分离了两种稳定形式。为了建立其结构，进行了B3LYP几何构型和能级的计算，并使用可极化连续体模型对可能的构象体进行了GIAO / B3LYP NMR计算。计算光谱的差异允许通过其1 H和13 C NMR归因于计算结构和获得的物质。构象比与其计算的吉布斯能量相关。
• 4-Acylhydrazinomethylene-2-phenyloxazol-5(4H)-ones as Acylating Agents: Synthesis of Salicylanilides and 1,2,4-Triazolo[4,3-b]pyridazines
  作者：Marijan Kočevar、Franc Pozgan、Slovenko Polanc

  DOI：10.3987/com-00-s(i)73

  日期：——
• US7268136B2
  申请人：——

  公开号：US7268136B2

  公开（公告）日：2007-09-11
• Structure-based design of 3-aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase
  作者：Ron Grey、Albert C. Pierce、Guy W. Bemis、Marc D. Jacobs、Cameron Stuver Moody、Rahul Jajoo、Narinder Mohal、Jeremy Green

  DOI：10.1016/j.bmcl.2009.04.061

  日期：2009.6

  A series of substituted 3-aryl-6-amino-triazolo[4,3-b]pyridazines were identified as highly selective inhibitors of Pim-1 kinase. Initial exploration identified compound 24 as a potent, selective inhibitor, limited in its utility by poor solubility and permeability. Understanding the unusual ATP-binding site of the Pim kinases and X-ray crystallographic data on compound 24 led to design improvements in this class of inhibitor. This resulted in compound 29, a selective, soluble and permeable inhibitor of Pim-1. (C) 2009 Elsevier Ltd. All rights reserved.
• Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold
  作者：Paul Galatsis、Jaclyn L. Henderson、Bethany L. Kormos、Seungil Han、Ravi G. Kurumbail、Travis T. Wager、Patrick R. Verhoest、G. Stephen Noell、Yi Chen、Elie Needle、Zdenek Berger、Stefanus J. Steyn、Christopher Houle、Warren D. Hirst

  DOI：10.1016/j.bmcl.2014.07.052

  日期：2014.9

  Leucine rich repeat kinase 2 (LRRK2) has been genetically linked to Parkinson's disease (PD). The most common mutant, G2019S, increases kinase activity, thus LRRK2 kinase inhibitors are potentially useful in the treatment of PD. We herein disclose the structure, potential ligand-protein binding interactions, and pharmacological profiling of potent and highly selective kinase inhibitors based on a triazolopyridazine chemical scaffold. (C) 2014 Elsevier Ltd. All rights reserved.